Sandoz news

EUR 175M investment enhances penicillin production and biosimilar development, improving ecological footprint and securing European supply. Supported by Austrian and Bavarian governments.

The $400M investment aims to boost biosimilar production, with operations starting in 2026. This supports the company's growth in biosimilars and antibiotics, enhancing access to critical medicines.

The spin-off aims to create a leading European generics and global biosimilars company, enhancing focus and growth for both entities, with completion expected in H2 2023, subject to approvals.